Prasad’s FDA appointment pressures cell and gene therapy stocks

A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

By Ben Fidler • May 7, 2025

After an up and down year, pharma’s R&D landscape is shifting again

While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

By Kelly Bilodeau • May 5, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

With compounders out of the way, Lilly and Novo go after each other

The two obesity leaders are pulling on all levers to stay on top of the market.

By Amy Baxter • May 5, 2025

Is pharma ready to let go of animal testing?

Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

By Meagan Parrish • May 2, 2025

Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

By Michael Gibney • May 1, 2025

US backlash against mRNA vaccines could hinder scientific progress

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

By Michael Gibney • April 29, 2025

Will Cobenfy’s clinical stumble derail a once-predicted rise?

BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.

By Kelly Bilodeau • April 28, 2025

What’s being cut at NIH

A look at the government’s far-reaching rollback in research grants so far.

By Meagan Parrish • April 25, 2025

Flagship’s latest venture reflects more than 25 years of leaping into the unknown

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

By Michael Gibney • April 24, 2025

Genetic breakthroughs could point pharma to a long COVID drug

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

By Kelly Bilodeau • April 22, 2025

Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

By Amy Baxter • April 21, 2025

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

By Alexandra Pecci • April 16, 2025

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

By Ned Pagliarulo • April 9, 2025

Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape

The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.

By Alexandra Pecci • April 9, 2025

Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

By Michael Gibney • April 8, 2025

US vs. EU: When it comes to novel Alzheimer’s drugs, regulators can’t seem to agree

The FDA is much more flexible in approving first-in-class drugs compared to European regulators.  

By Amy Baxter • April 7, 2025

A birth control pill for men makes moves in the clinic

So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

By Kelly Bilodeau • April 7, 2025

The year’s biggest biotech haul shows investors are still chasing the AI dream

Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.

By Meagan Parrish • April 4, 2025

Industry leaders react to HHS being ‘reduced to a shell’

What healthcare watchdogs have said about the far-reaching job cuts this week.

By Meagan Parrish and Amy Baxter • April 3, 2025

Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.

By Michael Gibney • April 1, 2025

With government health info in limbo, drugmakers lose credible sources

The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

By Alexandra Pecci • April 1, 2025

A recent gene therapy death shines a light on AAV safety

This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

By Kelly Bilodeau • March 31, 2025

In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.  

By Amy Baxter • March 31, 2025